Clinical Trials in Ulyanovsk, Russia
8 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
AsthmaChronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca110 enrolled9 locationsNCT07399665
Recruiting
Phase 2
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Chronic Kidney Disease With High Proteinuria
AstraZeneca224 enrolled15 locationsNCT06942910
Recruiting
Phase 3
The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients
RhinosinusitisRhinosinusitis Acute
Materia Medica Holding552 enrolled44 locationsNCT06901297
Recruiting
Phase 4
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, Inflammation
Novartis Pharmaceuticals1,000 enrolled167 locationsNCT04638647
Recruiting
Phase 3
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Multiple Sclerosis
Hoffmann-La Roche500 enrolled44 locationsNCT06675955
Recruiting
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Phase 2
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
Ulcerative Colitis (UC)
Biocad198 enrolled20 locationsNCT07080034
Recruiting
Phase 2
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
Crohn's Disease (CD)
Biocad204 enrolled20 locationsNCT07078994